Compare AbbVie Inc (ABBV) vs Charles Schwab Corporation Common Stock (SCHW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Charles Schwab Corporation Common Stock — how do they compare? AbbVie Inc trades at $253.69 (market cap $449.91B), while Charles Schwab Corporation Common Stock trades at $102.49 (market cap $177.27B). The key difference: AbbVie Inc is far larger — about 2.5× Charles Schwab Corporation Common Stock's market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | SCHW | |
|---|---|---|
Market Cap | $449.91B | $177.27B |
Sector | Health | Financials |
52-Week High | $261.07 | $107.21 |
52-Week Low | $184.85 | $85.35 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | 1.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
Charles Schwab (SCHW) trades at $101.93, up 5.08% with strong technical momentum and bullish moving averages. The stock shows robust fundamentals with a 37.99% net income margin and consistent earnings beats, including Q1 2026 EPS of $1.43 exceeding expectations. Recent news highlights retail trading growth and a new prediction market venture with Cboe, supporting positive sentiment.
Outlook remains favorable with a $120.38 analyst price target implying 18% upside, though overbought RSI signals near-term caution. Key risks include interest rate sensitivity and competitive pressures. Wall Street consensus is bullish with 58% buy ratings, reflecting confidence in Schwab's revenue diversification and asset growth trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Charles Schwab Corporation Common Stock
Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.
Read more on SCHW →
